Lessons From the ARCHER Trial - Top-Institutions - MDSpire

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

  • By

  • Margaret Chang, MD

  • July 15, 2026

  • 2 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Oncology

  • #2

    National Institutes of Health
    National Institutes of Health

    Bethesda, MD

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

Lessons From the ARCHER Trial

  • by Margaret Chang, MD

  • July 15, 2026

Related Content

Glaucoma in the UK

Largest-ever UK glaucoma patient survey launches to shape future eye care services in the country

  • July 16, 2026

  • 3 min
ASRS President Reflects on a Year of Change

As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.

Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy